Project description
Drug-induced tissue damage and immune response analysis platform
Presently, preclinical toxicity testing does not take into account drug-induced tissue damage and the associated risk for developing secondary autoimmune disease. FDA estimates that there are currently 300 drugs on the market that cause drug-induced autoimmune-mediated interstitial lung disease and strongly advocates the development for the inclusion of tests for preclinical analysis of adverse effects. The EU-funded PHIVIDIAS project enables the United Kingdom CRO Immundz to focus on the development of a unique and innovative platform for comprehensive preclinical study of drug-induced tissue damage and the immune response against molecules released from the damaged cells. The testing platform will be animal-free and will integrate a computational model for risk assessment for developing secondary autoimmune disease.
Objective
Drug-induced tissue damage and the associated risk for developing auto-immune secondary disease is fully ignored in preclinical toxicity testing. As a consequence, there are currently 300 drugs on the market that cause drug-induced auto-immune-mediated interstitial lung disease. In their regulatory documents, EMA and FDA strongly advocate for inclusion of tests to address this type of adverse effects in preclinical research. Immundz (www.immundnz.com) addresses this market opportunity by developing a unique and innovative platform, PHIVIDIAS, for comprehensive preclinical analysis of drug-induced tissue damage and the immune response against molecules released from the damaged cells, together with a computational model for risk assessment for developing auto-immune secondary disease. The testing platform will be animal free. Key persons from the client networks and a variety of other small and large companies have already been approached to assess their interest in the PHIVIDIAS platform. Their feedback identified a significant need for the PHIVIDIAS test platform and a variety of companies expressed their commitment to use the services. With PHIVIDIAS, Immundnz will be first in the market.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine pharmacology and pharmacy drug discovery
- medical and health sciences basic medicine immunology
- medical and health sciences basic medicine pathology
You need to log in or register to use this function
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3. - PRIORITY 'Societal challenges
See all projects funded under this programme -
H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-1 - SME instrument phase 1
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-EIC-SMEInst-2018-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
SK10 4TG Alderley Edge
United Kingdom
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.